



CASE ON/4-32344A

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

21783071215  
Express Mail Label Number

February 28, 2005  
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF  
AVRAMIS ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP03/02029

FILED: 27 FEBRUARY 2003

U.S. APPLICATION NO: 10/505,399

35 USC §371 DATE: 19 AUGUST 2004

FOR: COMBINATIONS OF (A) AN ATP-COMPETITIVE INHIBITOR OF C-  
ABL KINASE ACTIVITY WITH (B) TWO OR MORE OTHER  
ANTINEOPLASTIC AGENTS

**MS: Amendment**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.


In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references were cited in the international stage search report. Since these references are of record in the instant PCT application PCT/EP03/02029, copies are not enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,


Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(862) 778-7852

  
Oona A. Jackson  
Attorney for Applicants  
Reg. No. 48,152

Date: *2/20/05*

## INFORMATION DISCLOSURE CITATION

(Use separate sheets if necessary)

ATTY. DOCKET NO.  
ON/4-32344A  
APPLICATION NO.  
10/505,399  
APPLICANT  
AVRAMIS ET AL.  
FILING DATE  
AUGUST 19, 2004

Group

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA					
	AB					
	AC					
	AD					
	AE					
	AF					
	AG					
	AH					
	AI					
	AJ					
	AK					
	AL					

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO	
	AM					<input type="checkbox"/>	<input type="checkbox"/>
	AN					<input type="checkbox"/>	<input type="checkbox"/>
	AO					<input type="checkbox"/>	<input type="checkbox"/>
	AP					<input type="checkbox"/>	<input type="checkbox"/>
	AQ					<input type="checkbox"/>	<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	Ottaviani et al., "Simultaneous in vitro exposure to Glivec (formerly STI571), Apo2L/TRAIL and Interferon-alpha, with or without prior Ara-C treatment, Apo2L/TRAIL-induced cytotoxicity and apoptosis in BCR/ABL + leukemic blasts," Blood, Vol. 98(11), Part 2, pp. 265b-266b (2001)
AS	Marley et al., "Effects of combinations of therapeutic agents on the proliferation of progenitor cells in chronic myeloid leukaemia," British Journal of Haematology 2002, Vol. 116(1), pp. 162-165 (2002)
AT	"Chronic Myelogenous Leukemia and Investigational Treatment Strategies," Leukemia Insights, Online!, Vol. 6(3), pp. 1-8 (2001)

EXAMINER

DATE CONSIDERED


\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

ATTY. DOCKET NO.  
CN/4-32344A  
APPLICATION NO.  
10/505,399  
APPLICANT  
AVRAMIS ET AL.  
FILING DATE  
AUGUST 19, 2004

Group



**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent pages, Etc.)

DA	Topaly et al., "Synergistic activity of STI571 with chemotherapeutic drugs and irradiation," Blood, Vol. 96(11), Part 1, p. 736a (2000)
DB	Druker Brian J et al., "A phase I study of Gleevec (imatinib mesylate) administered concomitantly with cytosine arabinoside (Ara-C) in patients with Philadelphia positive chronic myeloid leukemia (CML)," Blood, Vol. 98(11), Part 1, pp. 845A-846A (2001)
DC	Ruchatz et al., "Co-administration of STI571 and idarubicin increases the sensitivity to cytotoxic treatment in vitro and in vivo," Blood, Vol. 98(11), Part 1, pp. 101a-102a (2001)
DD	Keating, "Leukemia: a model for drug development," Clinical Cancer Research, The American Association for Cancer Research, US, Vol. 3(12), Part 2, pp. 2598-2604 (1997)
DE	Berman et al., "Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia," Blood, Vol. 77(8), p. 1666-1674 (1991)
DF	Rosee La et al., "Insights from pre-clinical studies for new combination treatment regimens with the BCR-ABL kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective," Leukemia, Vol. 16(7), pp. 1213-1219 (2002)
DG	
DH	
DI	
DJ	
DK	
DL	
DM	
DN	

**EXAMINER**

**DATE CONSIDERED**

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.